Development and study of S100 calcium-binding protein B and Neuron-specific enolase-based predictive model for epilepsy secondary to cerebral infarction.

This study aimed to develop and validate a predictive model based on S100 calcium-binding protein B (S100B) and neuron-specific enolase (NSE) as the core of epilepsy secondary to cerebral infarction. For this aim, 156 cases of cerebral infarction from June 2018 to December 2019 were selected. According to the ratio of 7:3, 109 cases were used for training and 47 cases were used for validation.

Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.

Background: Neoadjuvant chemotherapy with S-1 plus oxaliplatin (SOX regimen) has shown promising results in pathological response rate and survival rate in patients with locally advanced resectable gastric cancer (LAGC). We previously carried out the SPACE study to assess efficacy and safety of low-dose apatinib combined with camrelizumab and the SOX regimen as a first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC/GEJC). The preliminary results demonstrated a high objective response rate.

Identification of lysine-lactylated substrates in gastric cancer cells.

Cancer cells tend to utilize aerobic glycolysis to generate energy and metabolites; the end product of aerobic glycolysis is lactate, which promotes lysine lactylation (Kla). Kla is a newly discovered histone post-translational modification (PTM) that plays important roles in regulating gene expression. However, Kla in non-histone mammalian proteins is unclear.

Case fatality rate of the adult in-patients with COVID-19 and digestive system tumors: A systematic review and meta-analysis.

Background: During the coronavirus disease 2019 (COVID-19) pandemic, endoscopic screening for gastrointestinal tumors was suspended or delayed in most countries. Thus, our study aimed to quantify the impact of COVID-19 on the clinical outcomes of patients with digestive system tumors through a systematic review and meta-analysis.

Methods: We systematically searched the PubMed, Web of Science, Cochrane Library, and Embase databases as of March 7, 2021 to identify the case fatality rate (CFR) of COVID-19 patients diagnosed with digestive system tumors.

Increasing miR-126 Can Prevent Brain Injury after Intracerebral Hemorrhage in Rats by Regulating ZEB1.

Background: Studies have found that microRNA (miR) is abnormally expressed in intracerebral hemorrhage (ICH) and is considered a therapeutic target for ICH.

Objective: To investigate the expression and role of miR-126 in the ICH rat model.

Methods: The ICH rat model was established, and miR-126 agomir and ZEB1 antagomir were injected into the lateral ventricle of ICH rats.

Yes-associated protein gene overexpression regulated by β-catenin promotes gastric cancer cell tumorigenesis.

Background: Yes-associated protein (YAP) has been reported to act as a candidate human oncogene and played a critical role in the development of multiple cancer types.

Objective: We aimed to investigate the expression, function, and underlying mechanisms of YAP in gastric cancer (GC).

Methods: Expression levels of YAP in gastric tissues were tested.

Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.

Background: The standard treatment for advanced gastric/gastroesophageal junction cancer (AGC/GEJC) is palliative chemotherapy combined with targeted therapy. The SOX regimen (S-1 plus oxaliplatin) is recommended as neoadjuvant or palliative first-line chemotherapy in Asian patients. Apatinib, an oral VEGFR tyrosine kinase inhibitor, is associated with additional survival benefit as third- or subsequent-line therapy.

FK506 ameliorates osteoporosis caused by osteoblast apoptosis via suppressing the activated CaN/NFAT pathway during oxidative stress.

Objective: Osteoporosis is affecting the health of postmenopausal women in the world. In case of that, we explored whether FK-506 could ameliorate osteoporosis by inhibiting the activated CaN/NFAT pathway during oxidative stress.

Methods: First, the castrated rat model is constructed through the bilateral ovariectomy.

A colonic metastasis from extrahepatic cholangiocarcinoma after removal of primary tumor: a case report and literature review.

Metastatic cholangiocarcinoma (CCA) to the gastrointestinal tracts has rarely been described in the literature. We report a 54-year-old male patient with radical resection of an extrahepatic CCA who underwent uncommon metastatic pattern. After a recurrence-free period of 2 years, an elevated CA19- 9 initiated a CT scan, showing a tumor at the junction of rectum and sigmoid with enlarged lymph nodes around colon, mimicking a primary colon cancer.

Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7.

The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC). However, in terms of safety, apatinib toxicities may lead to a dose modification or treatment interruption. Therefore, proper intervention is urgently needed to help patients benefit from apatinib treatment.